Lifestyle Effectiveness of Condoms

Effectiveness of condoms

If a condom is used properly during sexual intercourse, an individual may reduce the risk of acquiring or transmitting STDs, including HIV. Several studies show that using condoms correctly and consistently may reduce the breakage rates of latex condoms to less than two percent.

There are many types and brands of condoms, but only latex or polyurethane condoms have been shown to effectively prevent HIV transmission when used appropriately. According to the CDC, natural membrane condoms, such as those made with lambskin, have natural pores that can possibly transmit diseases. Therefore, lambskin condoms are not considered to be effective in preventing HIV transmission.

Recent evidence has suggested that condom use by high-risk populations increases, rather than decreases the infection rate. According to the latest studies, condom promotion is only effective in lowering the rate of AIDS in concentrated, high-risk groups; condoms have never been shown to reduce HIV infection rates and AIDS deaths in general-population epidemics like those in sub-Saharan Africa. In on study, researchers asserted that of the three interventions scientifically shown to prevent AIDS – abstinence, being faithful, and using condoms – they argue that the use of condoms clearly comes last and should be promoted as a first-line defense only to those in extremely high-risk groups, such as commercial sex workers.

One prospective study showed that for ‘receptive’ men during anal sex, it made little or no difference whether their partners used a condom or not. Researchers suggested that condoms are less effective in anal sex than in vaginal sex.

Selected References
AIDS.org. www.aids.org. Accessed March 29, 2009.
American Foundation for AIDS Research (amfAR). www.amfar.org. Accessed March 29, 2009.
Centers for Disease Control and Prevention (CDC). www.cdc.gov. Accessed March 29, 2009.
Elizabeth Glaser Pediatric AIDS Foundation. www.pedaids.org. Accessed March 29, 2009.
Halperin DT, Steiner MJ, Cassell MM, et al. The time has come for common ground on preventing sexual transmission of HIV. Lancet. 2004 Nov 27-Dec 3;364(9449):1913-5.
Loutfy MR, Antoniou T, Shen S, et al. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting. HIV Clin Trials. 2007 Jan-Feb;8(1):36-44.
National Institute of Allergy and Infectious Diseases (NIAD). www.niaid.nih.gov. Accessed March 29, 2009.
Natural Standard: The Authority on Integrative Medicine. www.naturalstandard.com. Copyright © 2009. Accessed March 29, 2009.
Rigopoulos D, Gregoriou S, Paparizos V, et al. AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy and management of obstetric, anesthetic, and pediatric issues. Skinmed. 2007 Mar-Apr;6(2):79-84.
The Body: The Complete HIV/AIDS Resource. www.thebody.com. Accessed March 29, 2009.
U.S. Food and Drug Administration (FDA). www.fda.gov. Accessed March 29, 2009.
Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: a review. Expert Opin Pharmacother. 2007 Apr;8(6):851-71.